Clinical Trial Associate (CTA) Certification Exam — Questions and Answers

Question 1: When a site investigator is temporarily unavailable, which action is acceptable under GCP?

Any site staff member may assume investigator duties
The sponsor's medical monitor automatically assumes all investigator responsibilities
A qualified sub-investigator listed on the FDA Form 1572 may perform delegated duties (Correct answer)
The CRA may act as the investigator until the PI returns

Correct answer: A qualified sub-investigator listed on the FDA Form 1572 may perform delegated duties

Only qualified individuals listed on the delegation log and, in the US, on FDA Form 1572 may perform investigator-delegated duties.

Question 2: A participant who is illiterate wants to enroll in a clinical trial. Which approach is acceptable for obtaining informed consent?

Obtain only verbal consent and document it in the medical record without a signature
Skip the consent form since the participant cannot read it
Have the participant sign an X and have a witness sign attesting to the verbal consent process (Correct answer)
Allow a family member to sign the consent form on the participant's behalf without witness

Correct answer: Have the participant sign an X and have a witness sign attesting to the verbal consent process

For illiterate participants, an impartial witness must be present during the entire consent process and sign the form along with the participant's mark.

Question 3: When must a site report an unexpected serious adverse drug reaction (SUSAR) to the regulatory authority?

Within 30 days of the subject's next scheduled visit
Only at the end of the annual safety report
Within 7 days for fatal/life-threatening events and 15 days for other unexpected serious adverse reactions (Correct answer)
Within 90 days of first awareness

Correct answer: Within 7 days for fatal/life-threatening events and 15 days for other unexpected serious adverse reactions

SUSARs that are fatal or life-threatening must be reported within 7 calendar days, and all other SUSARs within 15 calendar days.

Question 4: When archiving trial documents at study close-out, the minimum retention period required by ICH E6(R2) after study completion is:

2 years
At least 2 years after the last marketing approval, or at least 2 years if no approval (Correct answer)
10 years from protocol approval
5 years from last subject visit

Correct answer: At least 2 years after the last marketing approval, or at least 2 years if no approval

ICH E6(R2) requires essential documents to be retained for at least 2 years after the last approval of a marketing application or 2 years after formal discontinuation.

Question 5: Under ICH E6(R2), which of the following is NOT considered an essential document that must be in the Trial Master File before the trial begins?

IRB/IEC approval letter
Completed Case Report Forms (CRFs) (Correct answer)
Signed protocol and amendments
Investigator's brochure (IB)

Correct answer: Completed Case Report Forms (CRFs)

Completed CRFs are generated during the trial, not before it begins; they are essential documents maintained during the conduct phase, not the pre-trial phase.

Question 6: A CTA is responsible for reviewing open queries before a data lock. What is the correct priority for resolving a query marked 'critical'?

Resolve it immediately, as critical queries affect primary endpoint data or subject safety decisions (Correct answer)
Address it after resolving all routine queries
Mark it as 'not applicable' if the data cannot be retrieved
Escalate it to the FDA before taking any action

Correct answer: Resolve it immediately, as critical queries affect primary endpoint data or subject safety decisions

Critical queries typically involve primary efficacy endpoints, safety data, or eligibility criteria — they must be resolved before database lock and take priority over routine data cleaning.

Question 7: What is the purpose of a Type B meeting with the FDA during clinical development?

To obtain accelerated approval status
To discuss Phase 2 trial design and endpoints before Phase 3 initiation (Correct answer)
To negotiate manufacturing site inspections
To review post-market safety data after approval

Correct answer: To discuss Phase 2 trial design and endpoints before Phase 3 initiation

Type B meetings include End-of-Phase 2 and Pre-NDA/BLA meetings used to align on Phase 3 design before pivotal trials.

Question 8: A CTA is reviewing CRF completion rates before a monitoring visit. Which metric would BEST indicate a data quality concern?

100% query resolution rate
All CRF pages submitted within 7 days of the visit
High number of outstanding (open) queries older than 30 days (Correct answer)
Zero protocol deviations reported

Correct answer: High number of outstanding (open) queries older than 30 days

A large number of aged open queries indicates unresolved data discrepancies at the site, suggesting poor data quality management and potential source data verification issues.

Question 9: What is the purpose of a Clinical Study Report (CSR) as defined by ICH E3?

To summarize enrollment metrics for site staff
To report adverse events to regulatory authorities during the trial
To document investigator credentials and site qualifications
To provide an integrated report of the trial's methods, results, and conclusions (Correct answer)

Correct answer: To provide an integrated report of the trial's methods, results, and conclusions

ICH E3 defines the CSR as a comprehensive document integrating study methods, clinical results, and statistical analyses to support regulatory submissions.

Question 10: A participant enrolled in a blinded study asks the investigator to reveal their treatment assignment. What is the most appropriate response?

Notify the sponsor that the participant has withdrawn consent
Immediately unblind the participant and document it as a protocol deviation
Transfer the participant to a different site where their assignment can be revealed
Explain that unblinding is only done for medical necessity or at study end, per protocol procedures (Correct answer)

Correct answer: Explain that unblinding is only done for medical necessity or at study end, per protocol procedures

Unblinding during a trial is generally reserved for medical emergencies or as defined by the protocol, and investigators should explain this to participants.

Question 11: A subject is hospitalized for a planned surgical procedure that was scheduled before trial enrollment. How should this be classified?

Protocol deviation requiring IRB reporting
SAE — hospitalization always qualifies
Adverse Drug Reaction requiring immediate sponsor notification
Not an SAE if the hospitalization was pre-planned and unrelated to the trial (Correct answer)

Correct answer: Not an SAE if the hospitalization was pre-planned and unrelated to the trial

ICH E6 and most protocols exclude planned/elective hospitalizations that are unrelated to the study from SAE criteria, provided this exclusion is specified in the protocol.

Question 12: A participant's cognitive status deteriorates during the trial and they can no longer provide ongoing consent. What is the appropriate next step?

Immediately withdraw the participant without further evaluation
Continue the trial since initial consent was valid
Transfer responsibility for consent to the participant's primary care physician
Seek consent from a legally authorized representative and assess whether continued participation is in the participant's best interest (Correct answer)

Correct answer: Seek consent from a legally authorized representative and assess whether continued participation is in the participant's best interest

When a participant loses capacity, a legally authorized representative must assume the consent role, and the ethical appropriateness of continued participation must be evaluated.

Question 13: Under the ICH E6(R3) GCP guidelines, who is ultimately responsible for ensuring that informed consent is properly obtained?

The investigator (Correct answer)
The IRB/IEC that approved the consent form
The sponsor's clinical research associate
The regulatory authority that approved the trial

Correct answer: The investigator

ICH E6(R3) places ultimate responsibility on the investigator to ensure that informed consent is obtained before any trial-related procedures are conducted.

Question 14: A sponsor's clinical trial agreement specifies that the investigator must notify the sponsor within 24 hours of learning of a subject's death. This is an example of:

A contractual obligation that supplements GCP reporting requirements (Correct answer)
A DSMB recommendation without regulatory force
A voluntary guideline that can be waived by the investigator
An IRB requirement superseding the protocol

Correct answer: A contractual obligation that supplements GCP reporting requirements

Clinical trial agreements (CTAs) create contractual reporting obligations that may be stricter than minimum regulatory thresholds and are legally binding on both parties.

Question 15: A subject enrolled in a blinded trial inadvertently discovers their treatment assignment. According to GCP, what action is most appropriate?

Document the unblinding event, notify the investigator and sponsor, and assess impact on data integrity (Correct answer)
Continue the trial without any action since the subject is already enrolled
Automatically discontinue the subject and exclude their data
Remove the subject immediately without documentation

Correct answer: Document the unblinding event, notify the investigator and sponsor, and assess impact on data integrity

Unblinding events must be documented, reported, and assessed for their impact on trial integrity and subject safety per GCP requirements.

Question 16: What is the purpose of the Trial Master File (TMF)?

To manage drug shipments
To maintain essential trial documentation (Correct answer)
To store patient test results
To document financial records

Correct answer: To maintain essential trial documentation

The Trial Master File (TMF) is a collection of essential documents that individually and collectively permit the evaluation of the conduct of a clinical trial and the quality of the data produced. It serves as a central repository for all critical trial-related records, ensuring that the trial can be reconstructed and its compliance with GCP and regulatory requirements can be verified. The TMF is vital for audit and inspection readiness.

Question 17: What is the primary purpose of a drug accountability binder maintained at a clinical trial site?

To provide a centralized, auditable record of all IP transactions including receipts, dispensing, returns, and destruction (Correct answer)
To record financial payments made to participants for study drug costs
To store participant medical records alongside dispensing records
To file the sponsor's investigational new drug application supporting documents

Correct answer: To provide a centralized, auditable record of all IP transactions including receipts, dispensing, returns, and destruction

The drug accountability binder consolidates all IP transaction records in one location, enabling auditors and monitors to verify that all product is fully accounted for throughout the trial.

Question 18: Which GCP principle requires that clinical trial data be attributable, legible, contemporaneous, original, and accurate?

The Helsinki principle
The ALCOA principle (Correct answer)
The CIOMS principle
The CONSORT principle

Correct answer: The ALCOA principle

The ALCOA principle (Attributable, Legible, Contemporaneous, Original, Accurate) defines the required qualities for clinical trial data.

Question 19: In a clinical trial, 'source document verification' (SDV) refers to:

The sponsor verifying that the protocol was approved by the IRB
The process of comparing data in the CRF against original source documents to confirm accuracy (Correct answer)
Verifying that the investigator holds a valid medical license
Validating the eCRF software against regulatory requirements

Correct answer: The process of comparing data in the CRF against original source documents to confirm accuracy

SDV is the monitoring activity of comparing CRF entries against original source records (lab reports, medical charts, etc.) to confirm that data was accurately transcribed.

Question 20: In direct data capture (DDC), data is entered into the eCRF without paper source documents. Which of the following is a key validation requirement for DDC systems?

The eCRF must be printed and signed after each visit
Data must be re-entered by a second person for verification
DDC systems must use paper backup during each site visit
The system must be validated per 21 CFR Part 11 and the data must still be attributable, legible, contemporaneous, original, and accurate (Correct answer)

Correct answer: The system must be validated per 21 CFR Part 11 and the data must still be attributable, legible, contemporaneous, original, and accurate

DDC systems must be validated and meet 21 CFR Part 11 requirements; the eCRF itself serves as the source record, so ALCOA principles still apply.

Question 21: What documentation practice is considered essential in Protocol Development & Review within the Clinical Trial Associate field?

Completing all documentation at the end of the workday
Only documenting unusual events or complications
Recording actions, observations, and outcomes in real-time or as close to the event as possible (Correct answer)
Using shorthand notes that can be expanded later if needed

Correct answer: Recording actions, observations, and outcomes in real-time or as close to the event as possible

Real-time or near-real-time documentation in Protocol Development & Review ensures accuracy, provides a contemporaneous record, and is considered the gold standard for professional accountability and legal defensibility.

Question 22: Which element is classified as an 'additional' rather than 'basic' element of informed consent under 21 CFR 50.25?

A description of reasonably foreseeable risks
The expected duration of the participant's involvement
A description of the procedures to be followed
A statement that significant new findings will be disclosed to participants (Correct answer)

Correct answer: A statement that significant new findings will be disclosed to participants

Under 21 CFR 50.25(b), disclosing significant new findings that may affect willingness to continue is an additional element, not a required basic element.

Question 23: An IRB waives the requirement for written informed consent for a minimal-risk study. Which of the following conditions must be met for this waiver?

The study must involve only healthy volunteers with no pre-existing conditions
The sponsor must provide written approval of the waiver before the IRB grants it
The waiver must be renewed by the IRB every 30 days throughout the study
The research could not practicably be carried out without the waiver and involves no more than minimal risk (Correct answer)

Correct answer: The research could not practicably be carried out without the waiver and involves no more than minimal risk

Under 21 CFR 56.109(c) and 45 CFR 46.117(c), IRBs may waive written consent when the research involves minimal risk and cannot practicably be conducted otherwise.

Question 24: Which document defines the responsibilities and procedures for transferring sponsor obligations to a Contract Research Organization (CRO)?

Site Initiation Visit Report
Clinical Trial Agreement
Investigator Brochure
Sponsor-CRO Agreement (Correct answer)

Correct answer: Sponsor-CRO Agreement

A Sponsor-CRO Agreement formally documents the transfer of specific sponsor duties and liabilities to the CRO.

Question 25: Which international body harmonizes technical requirements for registration of pharmaceuticals for human use across the US, EU, and Japan through guidelines such as ICH E6?

International Council for Harmonisation (ICH) (Correct answer)
International Organization for Standardization (ISO)
Pharmaceutical Inspection Co-operation Scheme (PIC/S)
World Health Organization (WHO)

Correct answer: International Council for Harmonisation (ICH)

The International Council for Harmonisation (ICH) develops harmonized technical guidelines including GCP (E6), clinical study reports (E3), and CTD format (M4) used by regulatory authorities worldwide.

Question 26: A participant signs the consent form but later tells a nurse they did not understand what they signed. What is the most appropriate action?

Re-conduct the consent discussion to ensure comprehension, answer all questions, and have the participant re-sign if they still wish to participate (Correct answer)
Document the statement in the medical record and continue without further intervention
Withdraw the participant from the study immediately without further discussion
Reassure the participant and proceed since the signature is legally binding

Correct answer: Re-conduct the consent discussion to ensure comprehension, answer all questions, and have the participant re-sign if they still wish to participate

Informed consent is an ongoing process; if a participant indicates they did not understand, the consent discussion must be repeated and comprehension verified before continued participation.

Question 27: A monitoring visit reveals that a site coordinator has been pre-signing blank informed consent forms for convenience. This practice is:

Permitted during emergency situations only
Acceptable if the sponsor provides a waiver
Acceptable if the PI countersigns after the subject reads the form
A serious GCP violation because consent must be obtained through a proper interactive process before any study procedure (Correct answer)

Correct answer: A serious GCP violation because consent must be obtained through a proper interactive process before any study procedure

Pre-signing consent forms bypasses the required interactive consent process and constitutes a serious GCP violation regardless of subsequent PI review.

Question 28: Which FDA guidance describes the recommended format for electronic submissions to the Agency using the eCTD standard?

FDA Data Standards Catalog for Preclinical Submissions
Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications (Correct answer)
21 CFR Part 11 Electronic Records guidance
ICH M2 EWG on Electronic Standards for the Transfer of Regulatory Information

Correct answer: Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications

The FDA's eCTD guidance document specifies technical and format requirements for electronic Common Technical Document submissions.

Question 29: What is the primary purpose of the 'cooling-off' period sometimes allowed between consent and enrollment?

To ensure the investigator has completed all required training
To allow the IRB to verify the participant's eligibility criteria
To give participants time to reconsider their decision and consult with others before committing (Correct answer)
To allow the sponsor to review the consent form before the participant signs

Correct answer: To give participants time to reconsider their decision and consult with others before committing

A cooling-off period gives participants adequate time to reflect on their decision and discuss participation with family or advisors without pressure.

Question 30: When is it permissible under ICH E6(R2) for a legally acceptable representative (LAR) to provide consent on behalf of a subject?

When consent documentation is unavailable at the site
When the subject is unable to give personal informed consent due to incapacity (Correct answer)
When the subject refuses consent but the investigator believes participation is beneficial
When the sponsor waives the consent requirement for expedited enrollment

Correct answer: When the subject is unable to give personal informed consent due to incapacity

An LAR may consent when a subject lacks capacity to provide personal consent (e.g., due to cognitive impairment or emergency), provided applicable regulatory requirements are met.

Question 31: When must a site obtain a signed Financial Disclosure Form (FDA Form 3455 or equivalent) from clinical investigators in a US FDA-regulated trial?

Only if the investigator is also a sub-investigator at another site
At the end of the study when the clinical study report is compiled
Only for Phase III and IV studies
Before the study begins and updated if the investigator's financial interests change during the trial (Correct answer)

Correct answer: Before the study begins and updated if the investigator's financial interests change during the trial

FDA regulations require financial disclosures to be collected before the trial begins and updated if relevant financial interests change during the study to identify potential conflicts of interest.

Question 32: Which federal regulation specifically governs informed consent requirements for FDA-regulated clinical investigations in the United States?

45 CFR Part 164 (HIPAA Privacy Rule)
45 CFR Part 46 (the Common Rule)
21 CFR Part 312
21 CFR Part 50 (Correct answer)

Correct answer: 21 CFR Part 50

21 CFR Part 50 is the FDA regulation that establishes informed consent requirements for clinical investigations of FDA-regulated products.

Question 33: Which document formally authorizes a site to begin enrolling subjects in a clinical trial?

IRB/IEC approval letter (Correct answer)
Site Initiation Visit report
Feasibility questionnaire
Investigational New Drug Application

Correct answer: IRB/IEC approval letter

IRB/IEC approval is a mandatory regulatory prerequisite before any site may enroll study subjects.

Question 34: What does 21 CFR Part 11 regulate?

Electronic records and signatures (Correct answer)
IRB review procedures
Drug labeling
Clinical trial protocols

Correct answer: Electronic records and signatures

21 CFR Part 11 is a regulation issued by the U.S. Food and Drug Administration (FDA) that sets forth the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. It ensures the integrity, authenticity, and confidentiality of electronic data used in regulated industries, including clinical trials. This regulation is vital for the use of electronic systems in clinical research.

Question 35: Which regulatory agency requires IND safety reports (MedWatch Form FDA 3500A) for serious unexpected adverse drug reactions in the US?

ICH
OHRP
EMA
FDA (Correct answer)

Correct answer: FDA

The FDA requires IND safety reports using MedWatch Form FDA 3500A for serious unexpected adverse drug reactions occurring in US-regulated trials.

Question 36: Which essential document records the date, duration, findings, and follow-up actions from a monitoring visit?

Investigator Brochure
Monitoring Visit Report (Correct answer)
Site Qualification Report
Protocol Deviation Log

Correct answer: Monitoring Visit Report

A monitoring visit report documents all activities, observations, and action items from a specific site monitoring contact.

Question 37: What does the term 'capacity' mean in the context of informed consent?

The legal age threshold set by each state for medical decision-making
The maximum number of participants a site is authorized to enroll
The physical ability of a participant to complete all study visits
A participant's ability to understand information, appreciate its relevance, reason about options, and communicate a choice (Correct answer)

Correct answer: A participant's ability to understand information, appreciate its relevance, reason about options, and communicate a choice

Capacity refers to the cognitive and communicative ability to make an informed voluntary decision, distinct from legal competence.

Question 38: A CTA notices that an investigator has not submitted a required SAE report to the IRB within the protocol-specified 10-day window. What is the most appropriate immediate action?

Document the finding, notify the sponsor, and request the investigator submit the report promptly (Correct answer)
Record the deviation but take no further action until the next monitoring visit
Escalate to the FDA directly without informing the sponsor
Submit the SAE report to the IRB on behalf of the investigator

Correct answer: Document the finding, notify the sponsor, and request the investigator submit the report promptly

The CTA should document the finding as a protocol deviation, escalate to the sponsor, and work with the investigator to submit the overdue report as soon as possible.

Question 39: What is the key difference between a 'protocol violation' and a 'protocol deviation'?

Protocol violations are serious departures that may affect subject safety or data integrity; deviations are minor departures (Correct answer)
Protocol violations involve billing errors; deviations involve data errors
Protocol violations are intentional departures; deviations are unintentional
There is no difference—they are interchangeable terms

Correct answer: Protocol violations are serious departures that may affect subject safety or data integrity; deviations are minor departures

Protocol violations are serious departures from the protocol that may affect subject rights, safety, or data integrity, while deviations are minor unintended departures.

Question 40: In clinical trials, what does a p-value of less than 0.05 typically indicate?

The trial was properly blinded
The treatment is clinically meaningful
The result is statistically significant at the 5% level (Correct answer)
The study had sufficient sample size

Correct answer: The result is statistically significant at the 5% level

A p-value < 0.05 indicates that the observed result would occur less than 5% of the time by chance alone, meeting the conventional threshold for statistical significance.

Question 41: Which of the following scenarios represents a breach of informed consent documentation requirements under FDA regulations?

The consent form includes a statement about compensation for injury
The consent form is signed after a study-related blood draw has already been performed (Correct answer)
The consent form is printed in 12-point font
The consent form is stored in a locked file cabinet at the site

Correct answer: The consent form is signed after a study-related blood draw has already been performed

Performing any study-related procedure before obtaining signed informed consent violates 21 CFR 50.20, which requires consent prior to trial participation.

Question 42: Which ICH guideline provides guidance on statistical principles for clinical trials, including randomization and blinding?

ICH E3
ICH E6
ICH E9 (Correct answer)
ICH E8

Correct answer: ICH E9

ICH E9 — 'Statistical Principles for Clinical Trials' — covers randomization, blinding, analysis populations, and handling of missing data.

Question 43: When a conflict arises between standard procedures and a unique situation in Informed Consent Process, what should a CTA professional prioritize?

The most cost-effective solution available
Safety and ethical obligations while seeking expert consultation (Correct answer)
The preference of the client or stakeholder
Strict adherence to written procedures without exception

Correct answer: Safety and ethical obligations while seeking expert consultation

Safety and ethics always take priority in Informed Consent Process. When standard procedures don't adequately address a unique situation, consulting with experienced colleagues or supervisors ensures both safety and professional standards are maintained.

Question 44: What is the Medical Dictionary for Regulatory Activities (MedDRA)?

A database of approved drug doses and dosing schedules
A standardized international medical terminology used to code adverse events and medical conditions in clinical trials (Correct answer)
A clinical trial management software platform
A regulatory submission format for new drug applications

Correct answer: A standardized international medical terminology used to code adverse events and medical conditions in clinical trials

MedDRA is a globally harmonized, standardized medical terminology used by regulatory authorities and the pharmaceutical industry to code clinical data, including adverse events, in a consistent manner.

Question 45: Which of the following best describes 'therapeutic misconception' in clinical trial research?

An investigator's false assumption that all participants fully understand the consent form
A participant's incorrect belief that the study drug has already been approved by the FDA
A sponsor's misconception that informed consent eliminates all legal liability
A participant's mistaken belief that all trial procedures are tailored to their individual medical benefit rather than to generate generalizable knowledge (Correct answer)

Correct answer: A participant's mistaken belief that all trial procedures are tailored to their individual medical benefit rather than to generate generalizable knowledge

Therapeutic misconception occurs when participants confuse the purpose of research with individualized medical treatment, compromising the voluntariness of consent.

Question 46: Who is responsible for reviewing and approving a clinical trial protocol before the study begins at a specific site?

The CRA assigned to the site
The IRB/IEC and, where applicable, the regulatory authority (Correct answer)
The site's financial officer
Only the sponsor's clinical operations team

Correct answer: The IRB/IEC and, where applicable, the regulatory authority

Both the IRB/IEC and applicable regulatory authorities must review and approve the protocol before a study can begin at any site.

Question 47: Which of the following best describes the role of a Data Safety Monitoring Board (DSMB)?

To collect and enter case report form data on behalf of site staff
To audit sponsor financial records for compliance
To approve amendments to the study protocol
To independently review accumulating safety and efficacy data and recommend trial continuation, modification, or termination (Correct answer)

Correct answer: To independently review accumulating safety and efficacy data and recommend trial continuation, modification, or termination

A DSMB (or Data Monitoring Committee) independently reviews unblinded safety and efficacy data at interim points to protect subject safety and trial integrity.

Question 48: How often should GCP training be updated for clinical staff?

Never, if certified once
Only once
Every 5 years
Annually or as required by the institution (Correct answer)

Correct answer: Annually or as required by the institution

GCP training should not be a one-time event because regulations, guidelines, and best practices in clinical research are constantly evolving. Regular updates, typically annually or as mandated by the institution or sponsor, ensure that clinical staff remain current with the latest requirements. This continuous education helps maintain high standards of ethical conduct and data quality.

Question 49: When a subject withdraws from a clinical trial, the CRF should:

Document the withdrawal date, reason for withdrawal, and last known data points, then close the subject record appropriately (Correct answer)
Be left incomplete with no further notation
Be destroyed to protect the subject's privacy
Have all previously entered data deleted per HIPAA requirements

Correct answer: Document the withdrawal date, reason for withdrawal, and last known data points, then close the subject record appropriately

Withdrawal must be documented with the date, reason, and final data points; previously collected data is retained per the protocol and regulatory requirements unless the subject specifically requests data deletion (where permitted).

Question 50: In Informed Consent Process, what is the FIRST step a CTA professional should take when encountering a new case or situation?

Consult with a supervisor before taking any action
Conduct a comprehensive assessment and gather all relevant information (Correct answer)
Document the situation and wait for further instructions
Implement an immediate solution based on past experience

Correct answer: Conduct a comprehensive assessment and gather all relevant information

In Informed Consent Process, a thorough initial assessment ensures all relevant factors are identified before deciding on an appropriate course of action. This systematic approach is fundamental to Clinical Trial Associate practice.

Question 51: A site coordinator mistakenly enters data from Subject 105 into Subject 106's CRF in an eCRF system. What is the most appropriate course of action?

Silently correct the error in both records before anyone notices
Delete Subject 106's record and re-enter it from scratch
Contact the data management team immediately, document the error, correct both subject records with full audit trail entries and explanations (Correct answer)
Notify the IRB and suspend enrollment at the site

Correct answer: Contact the data management team immediately, document the error, correct both subject records with full audit trail entries and explanations

Data mix-ups between subjects require immediate notification of the data management team, transparent correction in both records, and full audit trail documentation to ensure data integrity.

Question 52: In a double-blind clinical trial, who is unaware of the treatment assignment?

Only the participant
Only the investigator
Both the participant and the investigator (Correct answer)
Only the sponsor

Correct answer: Both the participant and the investigator

In a double-blind study, both the participant and the investigator are unaware of treatment assignments to prevent performance and detection bias.

Question 53: Which ICH guideline specifically addresses clinical safety data management and definitions for expedited reporting?

ICH E3
ICH E2A (Correct answer)
ICH E9
ICH E6

Correct answer: ICH E2A

ICH E2A provides the definitions and standards for expedited safety reporting during clinical trials, including criteria for SUSARs and reporting timelines.

Question 54: A participant asks whether they can withdraw from the study at any time. Which response is most accurate according to GCP?

Participants may withdraw at any time without penalty or loss of benefits to which they are otherwise entitled (Correct answer)
Participants may withdraw but must complete the end-of-study visit to do so
Withdrawal is allowed but requires a 30-day notice period per protocol
Withdrawal is only permitted before the first dose of study drug is administered

Correct answer: Participants may withdraw at any time without penalty or loss of benefits to which they are otherwise entitled

GCP and 21 CFR 50.25(a)(8) require that participants be informed they may withdraw at any time without penalty or loss of otherwise entitled benefits.

Question 55: When must reconsent be obtained from a study participant?

Only when the study drug is changed to a new manufacturer
When the principal investigator changes institutions
Every six months regardless of protocol changes
When a protocol amendment adds new risks or substantially changes the nature of participation (Correct answer)

Correct answer: When a protocol amendment adds new risks or substantially changes the nature of participation

Reconsent is required when amendments introduce new information that could affect a participant's willingness to continue, such as new risks or significant procedural changes.

Question 56: What is the primary purpose of the Trial Master File (TMF)?

To serve as the comprehensive repository of all essential trial documents (Correct answer)
To summarize subject demographics for the clinical study report
To store financial invoices between sponsor and site
To record CRO employee training certificates only

Correct answer: To serve as the comprehensive repository of all essential trial documents

The TMF is the definitive collection of all essential documents demonstrating that the trial was conducted in compliance with GCP and regulations.

Question 57: What is the purpose of including 'exploratory endpoints' in a clinical trial protocol?

To satisfy IRB requirements for additional data collection
To provide backup data for regulatory submission
To replace the primary endpoint if it fails to show significance
To generate hypotheses and additional insights that may inform future studies, without being powered for definitive conclusions (Correct answer)

Correct answer: To generate hypotheses and additional insights that may inform future studies, without being powered for definitive conclusions

Exploratory endpoints generate hypothesis-generating data and additional insights but are not intended to provide definitive conclusions about treatment effects.

Question 58: During feasibility, a site reports 200 patients with the target diagnosis seen annually, but 80% are managed by physicians not involved in the study. How many potentially eligible patients per year should be estimated?

120
160
40 (Correct answer)
200

Correct answer: 40

Only 20% of the 200 patients (40) are managed by participating physicians and therefore realistically accessible for the study.

Question 59: What is the PRIMARY purpose of continuing education requirements in Data Collection & CRF Management for CTA professionals?

Earning additional credentials for career advancement
Networking with other professionals in the field
Maintaining current knowledge and competency as the field evolves (Correct answer)
Fulfilling mandatory regulatory requirements only

Correct answer: Maintaining current knowledge and competency as the field evolves

Continuing education in Data Collection & CRF Management ensures professionals maintain current knowledge and skills as standards, technologies, and best practices evolve in the Clinical Trial Associate field.

Question 60: How does risk management apply to daily practice in Study Startup & Feasibility for Clinical Trial Associate professionals?

Only through responding to incidents after they occur
By avoiding high-risk situations entirely
Through annual safety audits exclusively
Through proactive identification of potential hazards and implementation of preventive measures (Correct answer)

Correct answer: Through proactive identification of potential hazards and implementation of preventive measures

Effective risk management in Study Startup & Feasibility requires proactive hazard identification and preventive measures, not just reactive responses. This approach reduces incidents, improves outcomes, and protects both professionals and clients.

Question 61: Which EMA procedure allows a single marketing authorization application to be submitted and reviewed centrally for approval across all EU member states?

Decentralized Procedure
Centralized Procedure (Correct answer)
National Procedure
Mutual Recognition Procedure

Correct answer: Centralized Procedure

The Centralized Procedure is mandatory for certain drug classes and results in a single EMA marketing authorization valid in all EU/EEA countries.

Question 62: A CTA notices that the same site coordinator has been entering data for multiple subjects simultaneously using different browser tabs in the eCRF. What concern does this raise?

A breach of the investigator's financial disclosure obligations
A violation of the protocol's randomization procedures
Risk of data entry errors due to cross-contamination of subject data across tabs (Correct answer)
No concern — parallel entry is an efficient practice

Correct answer: Risk of data entry errors due to cross-contamination of subject data across tabs

Entering data for multiple subjects simultaneously across browser tabs increases the risk of entering the wrong data for the wrong subject, compromising data integrity.

Question 63: Which of the following best describes a 'protocol template' in the context of clinical trial operations?

The statistical analysis plan for a specific study
A standardized framework containing required sections that can be customized for specific studies (Correct answer)
A completed protocol approved by the FDA
A regulatory submission dossier

Correct answer: A standardized framework containing required sections that can be customized for specific studies

A protocol template is a standardized framework with required sections that sponsors use as a starting point, customizing it for each specific study.

Question 64: A protocol specifies that subjects must have a baseline HbA1c between 7.5% and 10%. A subject with HbA1c of 7.3% is enrolled. This is an example of:

A serious protocol violation requiring immediate reporting to the FDA
An eligibility protocol deviation that must be documented and reported (Correct answer)
A medical emergency requiring immediate intervention
An acceptable minor variation within measurement error

Correct answer: An eligibility protocol deviation that must be documented and reported

Enrolling a subject who does not meet the defined eligibility criteria constitutes an eligibility protocol deviation requiring documentation and reporting.

Question 65: How does risk management apply to daily practice in Informed Consent Process for Clinical Trial Associate professionals?

Through annual safety audits exclusively
Through proactive identification of potential hazards and implementation of preventive measures (Correct answer)
Only through responding to incidents after they occur
By avoiding high-risk situations entirely

Correct answer: Through proactive identification of potential hazards and implementation of preventive measures

Effective risk management in Informed Consent Process requires proactive hazard identification and preventive measures, not just reactive responses. This approach reduces incidents, improves outcomes, and protects both professionals and clients.

Question 66: Which standard of practice is MOST important for ensuring quality in Site Management & Monitoring?

Strictly adhering to the same procedure in every situation
Using the most advanced technology available regardless of need
Minimizing documentation to focus on practical work
Following evidence-based protocols while adapting to specific circumstances (Correct answer)

Correct answer: Following evidence-based protocols while adapting to specific circumstances

Evidence-based protocols provide a foundation of proven practices, but effective Clinical Trial Associate professionals must also adapt their approach based on specific circumstances and individual case needs within Site Management & Monitoring.

Question 67: A sponsor conducts a pre-study site qualification visit. The resulting qualification report is used to:

Inform the decision on whether the site is appropriate to participate in the trial (Correct answer)
Replace the need for a site initiation visit
Finalize payment terms with the site
Submit the IND application to the FDA

Correct answer: Inform the decision on whether the site is appropriate to participate in the trial

The qualification visit report documents assessment findings that the sponsor uses to decide whether the site meets criteria to conduct the trial.

Question 68: What is the significance of the Belmont Report's principle of 'respect for persons' to the informed consent process?

It requires that all participants receive monetary compensation for their time
It requires that all consent forms be written at a sixth-grade reading level
It mandates that individuals be treated as autonomous agents and that those with diminished autonomy receive special protections (Correct answer)
It prohibits the enrollment of any vulnerable populations in clinical trials

Correct answer: It mandates that individuals be treated as autonomous agents and that those with diminished autonomy receive special protections

Respect for persons requires acknowledging individual autonomy and providing additional protections for those with diminished capacity, forming the ethical basis for informed consent.

Question 69: A participant signs the consent form but then asks the study coordinator not to tell their spouse about their participation. How should the coordinator respond?

Document the spouse as a legally authorized representative in the study records
Inform the participant that while their records are confidential, their personal health disclosures are their own choice (Correct answer)
Contact the IRB immediately to report the participant's request
Refuse enrollment since confidentiality cannot be guaranteed to the spouse

Correct answer: Inform the participant that while their records are confidential, their personal health disclosures are their own choice

Confidentiality of study records is maintained by the research team; what participants share personally is their own decision.

Question 70: Which document must a sponsor maintain that lists all investigators authorized to conduct the clinical trial under an IND?

Form FDA 3500A
Form FDA 356h
Form FDA 1572 (Statement of Investigator) (Correct answer)
Form FDA 2253

Correct answer: Form FDA 1572 (Statement of Investigator)

FDA Form 1572 is signed by each investigator and describes their qualifications, commitments, and the study site, and is maintained in the IND.

Question 71: When reviewing the site's delegation log, the CRA notices tasks were performed by a staff member not listed on the log. What is the appropriate CRA action?

Remove the undocumented entries from the CRF retroactively
Ignore it if the tasks were performed correctly
Document the finding as a GCP deviation, notify the PI, and request an updated delegation log and training records (Correct answer)
Report the staff member directly to the FDA

Correct answer: Document the finding as a GCP deviation, notify the PI, and request an updated delegation log and training records

All individuals performing delegated study tasks must be documented on the delegation log; performing tasks without authorization is a GCP deviation requiring documentation and corrective action.

Question 72: Which regulatory framework provides the foundational international standard for the design, conduct, and reporting of clinical trials?

ISO 14155
ICH E6(R2) Good Clinical Practice (Correct answer)
HIPAA Privacy Rule
21 CFR Part 11

Correct answer: ICH E6(R2) Good Clinical Practice

ICH E6(R2) GCP is the internationally accepted standard for clinical trial conduct, accepted by regulatory authorities in the US, EU, and Japan.

Question 73: A subject in a clinical trial experiences a Grade 3 elevation in liver enzymes that resolves without sequelae. How should this be classified?

Adverse Event (AE) only
Adverse Drug Reaction (ADR)
Expected Adverse Event
Serious Adverse Event (SAE) (Correct answer)

Correct answer: Serious Adverse Event (SAE)

A Grade 3 laboratory abnormality that requires medical intervention meets the 'medically significant' criterion for classification as a Serious Adverse Event.

Question 74: ICH E6(R2) requires that changes to source data in paper records be made how?

By crossing out the original entry with a single line, dating, initialing, and providing a reason if needed (Correct answer)
By using correction fluid to cover the original entry
By deleting the original entry and rewriting it clearly
By attaching a separate memo without altering the original page

Correct answer: By crossing out the original entry with a single line, dating, initialing, and providing a reason if needed

GCP requires that corrections leave the original legible, crossed out with a single line, then dated, initialed, and explained if necessary, maintaining an audit trail.

Question 75: In an eCRF system, what does 'audit trail' refer to?

The final cleaned dataset submitted to regulatory authorities
A log of all site personnel who accessed the study database
A summary of protocol deviations identified during the trial
A chronological record of all data entries, modifications, and deletions with user identification and timestamps (Correct answer)

Correct answer: A chronological record of all data entries, modifications, and deletions with user identification and timestamps

An audit trail is a secure, computer-generated, time-stamped electronic record that allows reconstruction of the course of data entries and modifications by individual users.

Question 76: Which ICH guideline specifically addresses the statistical principles for clinical trials?

ICH E9 (Correct answer)
ICH E10
ICH E8
ICH E6

Correct answer: ICH E9

ICH E9 provides guidance on statistical principles for clinical trials, covering design, conduct, analysis, and reporting.

Question 77: According to ICH E6, what must an investigator do if a subject experiences an adverse event that is both serious and unexpected?

Report it to the sponsor immediately and follow up with a written report (Correct answer)
Wait until the end of the study to include it in the final report
Treat the adverse event and document it in the medical records only
Notify only the IRB within 30 days

Correct answer: Report it to the sponsor immediately and follow up with a written report

Serious and unexpected adverse events must be reported to the sponsor immediately, who then assesses whether expedited regulatory reporting is required.

Question 78: A prospective participant is in an acute pain crisis when approached for consent to a pain management trial. Which concern does this raise?

The investigator must obtain IRB approval before speaking to any participant in pain
Consent is valid as long as the participant signs the form regardless of their current condition
Pain may impair voluntary decision-making and comprehension, raising questions about the validity of consent obtained in this state (Correct answer)
Acute pain disqualifies a participant from all clinical trials by regulation

Correct answer: Pain may impair voluntary decision-making and comprehension, raising questions about the validity of consent obtained in this state

Acute distress or pain can compromise a person's ability to make a truly voluntary and fully informed decision, so consent obtained under these conditions may be ethically questionable.

Question 79: What is the purpose of including a statement about confidentiality limits in the informed consent form?

To satisfy insurance company requirements for trial coverage
To warn participants that their data may be sold to third-party marketers
To inform participants that regulatory authorities and sponsors may inspect records, limiting absolute confidentiality (Correct answer)
To notify participants that their physician will receive all study results

Correct answer: To inform participants that regulatory authorities and sponsors may inspect records, limiting absolute confidentiality

Participants must be told that while confidentiality will be maintained, records may be inspected by the FDA, sponsor, and IRB, so absolute privacy cannot be guaranteed.

Question 80: What is the key difference between a protocol deviation and a protocol violation in clinical trials?

Deviations are reported to the FDA; violations are not
A violation is a deviation that adversely affects subject safety, rights, or data integrity (Correct answer)
There is no meaningful distinction; the terms are interchangeable
Violations are intentional; deviations are always accidental

Correct answer: A violation is a deviation that adversely affects subject safety, rights, or data integrity

A violation is a deviation significant enough to compromise subject safety, rights, or study data integrity and typically requires immediate escalation.

Question 81: The 'washout period' in a crossover clinical trial is required to:

Eliminate residual effects of a previous treatment before the next intervention (Correct answer)
Allow subjects to rest between clinic visits
Meet minimum intervals mandated by the FDA for crossover designs
Reduce the total number of study participants needed

Correct answer: Eliminate residual effects of a previous treatment before the next intervention

A washout period allows the prior treatment's effects to dissipate before subjects receive the next intervention, preventing carryover bias.

Question 82: When a sponsor transfers trial-related duties to a CRO, ICH E6(R2) requires that:

A written agreement clearly specifying transferred duties is established (Correct answer)
The IRB must approve the CRO appointment
The investigator countersigns the CRO contract
The CRO assumes all sponsor regulatory obligations

Correct answer: A written agreement clearly specifying transferred duties is established

ICH E6(R2) requires a written agreement between the sponsor and CRO that defines which sponsor duties are delegated; the sponsor retains ultimate accountability.

Question 83: Under GCP, when a protocol deviation occurs at a site, what is the CTA's first responsibility?

Document the deviation and report it to the sponsor per the protocol and SOPs (Correct answer)
Notify the IRB/IEC before taking any other action
Correct the deviation silently to avoid regulatory attention
Immediately terminate the subject's participation

Correct answer: Document the deviation and report it to the sponsor per the protocol and SOPs

GCP requires that deviations be documented and reported to the sponsor according to the protocol and applicable SOPs so appropriate corrective action can be taken.

Question 84: What is a primary endpoint in a clinical trial?

The last timepoint of data collection
The number of participants who complete the study
The safety monitoring criteria
The main outcome measure used to assess the treatment's effect (Correct answer)

Correct answer: The main outcome measure used to assess the treatment's effect

The primary endpoint is the pre-specified main outcome measure that the trial is powered to evaluate and that drives the key efficacy conclusion.

Question 85: What action should a CTA take if they discover that an SAE was not reported within the required timeframe?

Wait until the next monitoring visit to address it
Instruct the site to back-date the report
Immediately notify the sponsor and document the deviation (Correct answer)
Amend the protocol to extend reporting timelines

Correct answer: Immediately notify the sponsor and document the deviation

A late SAE report is a protocol deviation that must be immediately escalated to the sponsor and fully documented to ensure transparency and regulatory compliance.

Question 86: What is a confidence interval (CI) used for in clinical trial reporting?

To calculate the required sample size
To express the range within which the true treatment effect likely falls (Correct answer)
To assign participants to treatment groups
To determine the optimal dose of a drug

Correct answer: To express the range within which the true treatment effect likely falls

A confidence interval provides a range of plausible values for the true treatment effect, with a 95% CI meaning the true value falls within that range 95% of the time.

Question 87: Which of the following best describes 'randomization codes' in a blinded clinical trial?

Codes used to encrypt electronic data transmissions
Unique numbers assigned to subject medical records for privacy
Numbers assigned to study sites for sponsor tracking purposes
Codes that determine each subject's treatment assignment and are kept confidential to maintain blinding (Correct answer)

Correct answer: Codes that determine each subject's treatment assignment and are kept confidential to maintain blinding

Randomization codes determine treatment assignments and are kept confidential to preserve blinding and prevent bias during the trial.

Question 88: What is the PRIMARY purpose of continuing education requirements in Informed Consent Process for CTA professionals?

Maintaining current knowledge and competency as the field evolves (Correct answer)
Networking with other professionals in the field
Earning additional credentials for career advancement
Fulfilling mandatory regulatory requirements only

Correct answer: Maintaining current knowledge and competency as the field evolves

Continuing education in Informed Consent Process ensures professionals maintain current knowledge and skills as standards, technologies, and best practices evolve in the Clinical Trial Associate field.

Question 89: A participant experiences a serious adverse event (SAE) mid-trial that is identified as a new risk. How does this affect the informed consent process?

The sponsor must halt the trial until all participants provide new consent
The site must withdraw the participant from the trial until the SAE is resolved
The IRB must be notified and may require a consent form amendment; currently enrolled participants may need to be reconsented (Correct answer)
No action is needed since the participant already signed the original consent form

Correct answer: The IRB must be notified and may require a consent form amendment; currently enrolled participants may need to be reconsented

New safety information that may affect participant willingness must be reported to the IRB, which may require a consent amendment and reconsent of enrolled participants.

Question 90: A CTA notices that the IRB-approved consent form version used at the site is six months out of date. What is the most appropriate immediate action?

Request a protocol deviation waiver from the sponsor
Continue using the old form until the next monitoring visit
Notify the investigator immediately so that the current IRB-approved version can be implemented and affected participants can be reconsented (Correct answer)
Have the site update the date on the old form to make it appear current

Correct answer: Notify the investigator immediately so that the current IRB-approved version can be implemented and affected participants can be reconsented

Using an outdated consent form is a protocol deviation; the site must switch to the current IRB-approved version immediately and reconsent participants if required.

Question 91: In EDC systems, 'edit checks' serve what primary function?

They automatically flag inconsistent, out-of-range, or logically impossible data entries at the point of data entry (Correct answer)
They encrypt data to prevent unauthorized access
They generate randomization codes for subject assignment
They send automatic study update notifications to investigators

Correct answer: They automatically flag inconsistent, out-of-range, or logically impossible data entries at the point of data entry

Edit checks (also called validation rules) are programmed into eCRF systems to detect data entry errors — such as impossible dates, out-of-range values, or missing required fields — in real time.

Question 92: What is the significance of source documentation in clinical trials?

To provide evidence of data accuracy (Correct answer)
To support regulatory submissions
To track budget allocations
To market the trial

Correct answer: To provide evidence of data accuracy

Source documentation refers to all original records and certified copies of clinical findings, observations, or other activities in a clinical trial. Its significance lies in providing direct evidence that the data reported in the Case Report Form (CRF) are accurate, complete, and verifiable. This ensures the integrity and reliability of the study results, which is crucial for regulatory scrutiny and the overall credibility of the trial.

Question 93: What is the role of an impartial witness during the informed consent process?

To verify that the participant meets the protocol's inclusion and exclusion criteria
To translate the consent form into the participant's native language
To attest that the information was accurately explained and that the participant voluntarily signed the consent form (Correct answer)
To countersign the form on behalf of the IRB as the oversight representative

Correct answer: To attest that the information was accurately explained and that the participant voluntarily signed the consent form

An impartial witness attests that the consent information was presented accurately and that the participant's consent was voluntary, serving as an independent verification of the process.

Question 94: Which of the following is an example of a serious adverse event (SAE) as defined by ICH E6?

Mild nausea lasting one day
Hospitalization for a condition unrelated to the study drug (Correct answer)
Temporary injection site redness
A missed dose of study medication

Correct answer: Hospitalization for a condition unrelated to the study drug

Any hospitalization, whether or not related to the study drug, meets the ICH E6 definition of a serious adverse event.

Question 95: Under ICH E6(R2), a sponsor's audit of a clinical trial site is best described as:

An IRB review of the protocol and consent forms
A systematic and independent examination of trial-related activities and documents by the sponsor (Correct answer)
A regulatory inspection conducted by a health authority
A routine site visit by the CRA to verify data entry

Correct answer: A systematic and independent examination of trial-related activities and documents by the sponsor

An audit is a sponsor-conducted, independent examination to evaluate whether trial activities and data comply with the protocol, SOPs, GCP, and applicable regulations.

Question 96: A sponsor receives a Complete Response Letter (CRL) from the FDA. What does this indicate?

The clinical trial may proceed to the next phase
The application cannot be approved in its current form and deficiencies must be addressed (Correct answer)
The FDA requires an advisory committee meeting before review
The drug has been approved with post-market commitments

Correct answer: The application cannot be approved in its current form and deficiencies must be addressed

A CRL means the FDA will not approve the application in its present form and outlines issues requiring resolution.

Question 97: What is the FDA's MedWatch program?

The FDA's safety information and adverse event reporting program for marketed medical products (Correct answer)
An FDA initiative to educate clinical investigators
A drug approval tracking system for sponsors
A program to monitor clinical trial site compliance

Correct answer: The FDA's safety information and adverse event reporting program for marketed medical products

MedWatch is the FDA's Safety Information and Adverse Event Reporting Program that allows healthcare professionals and the public to report serious adverse events associated with marketed drugs, biologics, and devices.

Question 98: How long should essential documents be retained after a clinical trial?

Until the study ends
Two years or as required by regulations (Correct answer)
Permanently
One year

Correct answer: Two years or as required by regulations

Essential documents for a clinical trial must be retained for a specific period to allow for reconstruction of the trial and verification of data. While a common guideline is at least two years after the last approval of a marketing application or until there are no pending or contemplated marketing applications, specific regulatory requirements (e.g., FDA, EMA) or sponsor policies may dictate longer retention periods. Adherence to these regulations is mandatory.

Question 99: A CTA notices that the protocol allows a ±3-day visit window for screening, but the site's standard scheduling system only allows exact-date appointments. What is the BEST resolution?

Document the site limitation and work with the site to implement a manual tracking system for the visit window (Correct answer)
Grant the site a blanket protocol deviation for all screening visits
Override the protocol and require exact-date visits only
Exclude the site from the study due to scheduling system incompatibility

Correct answer: Document the site limitation and work with the site to implement a manual tracking system for the visit window

Operational workarounds such as manual visit window tracking are acceptable solutions that allow the site to comply with the protocol without requiring system overhaul or protocol deviation.

Question 100: Which regulatory body oversees drug approval in the United States?

CDC
FDA (Correct answer)
EMA
WHO

Correct answer: FDA

The Food and Drug Administration (FDA) is the primary regulatory body in the United States responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. It reviews and approves new drugs before they can be marketed and sold to the public. The FDA's oversight is critical for consumer protection and drug development.

Clinical Trial Associate (CTA) Certification Exam

The CTA certification validates foundational knowledge and skills required for entry-level roles in clinical research, focusing on the operational aspects of clinical trials.

100

Questions

120 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds